MedTrace Logo

Safety, Tolerability and Efficacy Study to Evaluate Subjects With Mild Cognitive Impairment

NCT00422981 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 144

Last updated 2012-10-24

No results posted yet for this study

Summary

The purpose of this study is to find out if different doses of Investigational Drug are safe, tolerable, and if they have an effect on Mild Cognitive Impairment (MCI).

Conditions

  • Mild Cognitive Impairment, So Stated

Interventions

DRUG

AL-108

5 mg QD

DRUG

AL-108

15 mg BID

DRUG

Placebo

Placebo

Sponsors & Collaborators

  • Allon Therapeutics

    lead INDUSTRY

Principal Investigators

  • Donald E Schmechel, MD · Memory Assessment and Research Services

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
55 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-01-31
Primary Completion
2008-01-31
Completion
2008-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00422981 on ClinicalTrials.gov